Abstract
One of our most unusual clinical practices is to anticoagulate patients with heparin, an extract from bovine lung or porcine intestine, and reverse the heparin with protamine, a histone and a arginine rich polypeptide extracted from salmon sperm. Perhaps our practice of medicine is more medieval than we wish to realize. Furthermore, most clinicians managing patients during cardiac surgery have minimal understanding of the problems associated with anticoagulation and its reversal. Although cardiologists are evaluating different thrombin and platelet inhibitors to prevent graft reocclusion during angioplasty, there are few advances in the field of anticoagulation and reversal for cardiac surgical patients that are available for clinicians. This review will discuss the perspectives in anticoagulation and reversal, and novel agents on the horizon for heparin reversal.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Salzman EW, Hirsh J, Marder VJ. Clinical use of heparin. In: Colman RW HJ Marder VJ, Salzman EW, ed. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed. Philadelphia: J.B. Lippincott 1584–1591, 1994
Teasdale SJ, Zulys VJ, Mycyk T. Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis. Ann Thorac Surg 48:712–723, 1989
Cloyd GM, D’Ambra MN, Akins CW. Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 94:535–8, 1987
Zaidan JR, Johnson S, Brynes R, Monroe S, Guffin AV. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery. Anesth Analg 65:377–380, 1986
Anderson GP. Insights into heparin-induced thrombocytopenia. Br J Haematol 80:504–508, 1992
Hemker HC, Beguin S. Low molecular weight heparins: an introduction. Haemostasis 20(S):74–80, 1991
Levy JH, Cormack JG, Morales A. Heparin neutralization by recombinant platelet factor 4 and protamine. Anesth Analg 81:35–37, 1995
Stewart WJ, McSweeney SM, Kellett MR, Faxon DP, Ryan TJ. Increased risk of severe protamine reactions in NPH insulindependent diabetics undergoing cardiac catheterization. Circulation 70:788–792, 1984
Levy JH, Zaidan JR, Faraj BA. Prospective evaluation of risk of protamine reactions in NPH insulin-dependent diabetics. Anesth Analg 65:739–742, 1986
Levy JH, Schwieger IM, Zaidan JR, Faraj BA, Weintraub WS. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg 98:200–204, 1989
Wang JS, Lin CY, Hung WT, Karp RB. Monitoring of heparin-induced anticoagulation with kaolin activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 77:1080–1084, 1992
Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 193:105–11, 1981
Slaughter TF, LeBleu TH, Douglas JM, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 80:520–526, 1994
Montalescot G, Zapol WM, Carvalho A, Robinson DR, Torres A, Lowenstein E. Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep. Circulation 82:1754–1764, 1990
Williams RD, D’Ambra MN, Maione TE, Lynch KE, Keene DF. Recombinant platelet factor 4 reversal of heparin in human cardiopulmonary bypass blood. J Thorac Cardiovasc Surg 108:975–83, 1994
Cook JJ, Niewiarowski S, Yan Z, Schaffer L, Lu W, Stewart G J, Mosser DM, Myers JA, Maione TF. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes. Circulation 85:1102–1109, 1992
Kurrek MM, Winkler M, Robinson DR, Zapol WM. Platelet factor 4 injection produces acute pulmonary hypertension in the awake lamb. Anesthesiology 82:183–7, 1995
Dehmer GJ, Fisher M, Tate DA, Teo S, Bonnem EM. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans. Circulation 91:2188–2194, 1995
Hoving P, Linker A. The enzymatic degradation of heparin and heparitin sulfate, iii. Purification of a heparitinase and a heparinase from flavobacterium. J Biol Chem 245:6170, 1970
Michelsen LG, Kikura M, Lee MK, Szlam F, Levy JH. Heparinase as an alternative for reversing heparin anticoagulation. In Review
Zimmermann J, Lee K, Lambert C, Bier C. Efficacy and pharmacokinetics of heparinase, a novel and improved heparin-reversal agent, in rabbits. Catheterization and Cardiovascular Diag 32:88, 1994
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Kluwer Academic Publishers
About this chapter
Cite this chapter
Levy, J.H. (1996). New Concepts in Anticoagulation and Reversal. In: Stanley, T.H., Bailey, P.L. (eds) Anesthesiology and the Cardiovascular Patient. Developments in Critical Care Medicine and Anesthesiology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-1622-7_13
Download citation
DOI: https://doi.org/10.1007/978-94-009-1622-7_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-7224-3
Online ISBN: 978-94-009-1622-7
eBook Packages: Springer Book Archive